JP7120993B2 - 多能性細胞を分化させるための方法 - Google Patents

多能性細胞を分化させるための方法 Download PDF

Info

Publication number
JP7120993B2
JP7120993B2 JP2019508965A JP2019508965A JP7120993B2 JP 7120993 B2 JP7120993 B2 JP 7120993B2 JP 2019508965 A JP2019508965 A JP 2019508965A JP 2019508965 A JP2019508965 A JP 2019508965A JP 7120993 B2 JP7120993 B2 JP 7120993B2
Authority
JP
Japan
Prior art keywords
cells
inhibitor
days
signaling
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019508965A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019531062A (ja
Inventor
クリストファー ダブリュー マクマホン
ローレン イー リトル
ウェン ボ ワン
ナサニエル エイ エリオット
Original Assignee
フジフィルム セルラー ダイナミクス，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by フジフィルム セルラー ダイナミクス，インコーポレイテッド filed Critical フジフィルム セルラー ダイナミクス，インコーポレイテッド
Publication of JP2019531062A publication Critical patent/JP2019531062A/ja
Priority to JP2022035753A priority Critical patent/JP7600165B2/ja
Application granted granted Critical
Publication of JP7120993B2 publication Critical patent/JP7120993B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0619—Neurons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0623—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/22—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
    • C07C215/28—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C229/36—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/405—Cell cycle regulated proteins, e.g. cyclins, cyclin-dependant kinases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/41—Hedgehog proteins; Cyclopamine (inhibitor)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/415—Wnt; Frizzeled
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases [EC 2.]
    • C12N2501/727—Kinases (EC 2.7.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/73—Hydrolases (EC 3.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/70—Polysaccharides
    • C12N2533/80—Hyaluronan
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073—Stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Psychology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
JP2019508965A 2016-08-16 2017-08-16 多能性細胞を分化させるための方法 Active JP7120993B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022035753A JP7600165B2 (ja) 2016-08-16 2022-03-09 多能性細胞を分化させるための方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662375590P 2016-08-16 2016-08-16
US62/375,590 2016-08-16
PCT/US2017/047124 WO2018035214A1 (en) 2016-08-16 2017-08-16 Methods for differentiating pluripotent cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022035753A Division JP7600165B2 (ja) 2016-08-16 2022-03-09 多能性細胞を分化させるための方法

Publications (2)

Publication Number Publication Date
JP2019531062A JP2019531062A (ja) 2019-10-31
JP7120993B2 true JP7120993B2 (ja) 2022-08-17

Family

ID=59714142

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019508965A Active JP7120993B2 (ja) 2016-08-16 2017-08-16 多能性細胞を分化させるための方法
JP2022035753A Active JP7600165B2 (ja) 2016-08-16 2022-03-09 多能性細胞を分化させるための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022035753A Active JP7600165B2 (ja) 2016-08-16 2022-03-09 多能性細胞を分化させるための方法

Country Status (10)

Country Link
US (2) US10590383B2 (https=)
EP (3) EP4328301A3 (https=)
JP (2) JP7120993B2 (https=)
KR (2) KR102625865B1 (https=)
CN (2) CN109844102B (https=)
AU (2) AU2017313065B2 (https=)
CA (1) CA3033205A1 (https=)
DK (1) DK3500664T3 (https=)
ES (1) ES2901379T3 (https=)
WO (1) WO2018035214A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190018000A1 (en) 2016-01-12 2019-01-17 Cedars-Sinai Medical Center A method of non destructive monitoring of biological processes in microfluidic tissue culture systems
US11913022B2 (en) 2017-01-25 2024-02-27 Cedars-Sinai Medical Center In vitro induction of mammary-like differentiation from human pluripotent stem cells
US11767513B2 (en) 2017-03-14 2023-09-26 Cedars-Sinai Medical Center Neuromuscular junction
US12497591B2 (en) * 2018-03-07 2025-12-16 Sorbonne Universite Compositions and methods for efficient amplification of retinal progenitors cells
CN108456659B (zh) 2018-03-14 2020-05-05 浙江霍德生物工程有限公司 3d大脑类器官的制备方法
EP4700387A2 (en) 2018-03-23 2026-02-25 Cedars-Sinai Medical Center Methods of use of islet cells
WO2019195800A1 (en) 2018-04-06 2019-10-10 Cedars-Sinai Medical Center Novel differentiation technique to generate dopaminergic neurons from induced pluripotent stem cells
WO2019195798A1 (en) 2018-04-06 2019-10-10 Cedars-Sinai Medical Center Human pluripotent stem cell derived neurodegenerative disease models on a microfluidic chip
EP3787613B1 (en) 2018-04-30 2026-03-11 Cedars-Sinai Medical Center Pkc activation for use in treating early onset sporadic parkinson's disease
WO2020237104A1 (en) * 2019-05-23 2020-11-26 The Mclean Hospital Corporation Autologous cell replacement therapy for parkinson's disease
EP4021477A4 (en) * 2019-08-29 2023-12-13 Memorial Sloan Kettering Cancer Center METHOD FOR GENERATING AND ISOLATING MID-DOPAMINE NEURONS
EP4032974A4 (en) * 2019-09-20 2023-12-06 Korea Research Institute of Bioscience and Biotechnology Production method for induced dopaminergic neuronal progenitors, using direct reprogramming
KR20220158046A (ko) 2020-03-25 2022-11-29 사나 바이오테크놀로지, 인크. 신경계 장애 및 병태의 치료를 위한 면역저하성 신경 세포
US12104170B2 (en) 2020-06-26 2024-10-01 Minerva Biotechnologies Corporation Methods for deriving dopaminergic neurons from pluripotent stem cells
CN116635047A (zh) * 2020-06-26 2023-08-22 米纳瓦生物技术公司 用于从多能干细胞衍生多巴胺能神经元的方法
KR20230044539A (ko) * 2020-08-17 2023-04-04 인스티튜트 오브 주올로지, 차이니즈 아카데미 오브 사이언스 신경 세포를 위한 확장 배양 배지 및 배양 방법
CN114292814A (zh) * 2020-09-22 2022-04-08 上海跃赛生物科技有限公司 一种多能干细胞分化为中脑黒质多巴胺能神经细胞的方法
TWI808661B (zh) 2021-03-05 2023-07-11 日商旭化成股份有限公司 氧化還原液流電池用電極及氧化還原液流電池用電極之製造方法
WO2022216911A1 (en) 2021-04-07 2022-10-13 FUJIFILM Cellular Dynamics, Inc. Dopaminergic precursor cells and methods of use
CN115873797B (zh) * 2021-09-29 2024-08-13 北京干细胞与再生医学研究院 一种视网膜色素上皮细胞的扩增培养基及培养方法
EP4606888A1 (en) * 2022-10-20 2025-08-27 K Pharma, Inc. Novel production method for neural stem cell/neural progenitor cell
FR3151340A1 (fr) * 2023-07-21 2025-01-24 Treefrog Therapeutics Différenciation neurale à partir de cellules pluripotentes

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014532440A (ja) 2011-11-04 2014-12-08 メモリアル スローン−ケタリング キャンサー センター 移植用中脳ドーパミン（ｄａ）ニューロン
WO2015143342A1 (en) 2014-03-21 2015-09-24 Cellular Dynamics International, Inc. Production of midbrain dopaminergic neurons and methods for the use thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
CA2277278A1 (en) 1997-01-10 1998-07-16 Life Technologies, Inc. Embryonic stem cell serum replacement
US20020168766A1 (en) 2000-01-11 2002-11-14 Gold Joseph D. Genetically altered human pluripotent stem cells
WO2001088100A1 (en) 2000-05-16 2001-11-22 Kyowa Hakko Kogyo Co., Ltd. Novel method of inducing the differentiation of embryonic stem cells into ectodermal cells and use thereof
WO2001088104A2 (en) 2000-05-17 2001-11-22 Geron Corporation Neural progenitor cell populations
UY27224A1 (es) 2001-03-23 2002-10-31 Bayer Corp Inhibidores de la rho-quinasa
PE20020958A1 (es) 2001-03-23 2002-11-14 Bayer Corp Inhibidores de la rho-quinasa
WO2003006950A2 (en) 2001-07-12 2003-01-23 Geron Corporation Cells of the cardiomyocyte lineage produced from human pluripotent stem cells
US20030211603A1 (en) 2001-08-14 2003-11-13 Earp David J. Reprogramming cells for enhanced differentiation capacity using pluripotent stem cells
JP4505228B2 (ja) 2002-01-10 2010-07-21 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト Ｒｈｏ−キナーゼ阻害剤
MXPA04007196A (es) 2002-01-23 2005-06-08 Bayer Pharmaceuticals Corp Inhibidores de rho-quinasa.
EP1470121B1 (en) 2002-01-23 2012-07-11 Bayer HealthCare LLC Pyrimidine derivatives as rho-kinase inhibitors
ES2273047T3 (es) 2002-10-28 2007-05-01 Bayer Healthcare Ag Fenilaminopirimidinas sustituidas con heteroariloxi como inhibidores de rho-cinasa.
WO2005080554A1 (ja) 2004-02-23 2005-09-01 Kyoto University 胚性幹細胞の分化調節方法
WO2005123902A1 (ja) 2004-06-18 2005-12-29 Riken 無血清浮遊培養による胚性幹細胞の神経分化誘導法
AU2005282414C1 (en) 2004-09-08 2011-04-07 Wisconsin Alumni Research Foundation Culturing human embryonic stem cells
US20070116680A1 (en) 2005-11-18 2007-05-24 Rensselaer Polytechnic Institute Stem cells within gel microenvironments
WO2008089351A1 (en) 2007-01-17 2008-07-24 Wisconsin Alumni Research Foundation Improved culture of stem cells
EP3279314A1 (en) 2008-06-04 2018-02-07 Cellular Dynamics International, Inc. Methods for the production of ips cells using non-viral approach
ES2633935T3 (es) 2008-12-05 2017-09-26 Inserm - Institut National De La Santé Et De La Recherche Médicale Método y medio para la diferenciación neural de células pluripotentes
WO2010096496A2 (en) * 2009-02-17 2010-08-26 Memorial Sloan-Kettering Cancer Center Methods of neural conversion of human embryonic stem cells
WO2010141801A2 (en) 2009-06-05 2010-12-09 Cellular Dynamics International, Inc. Reprogramming t cells and hematophietic cells
DK2694644T3 (en) 2011-03-30 2018-04-16 Cellular Dynamics Int Inc Priming of pluripotent stem cells for neural differentiation
EP3031908B1 (en) 2013-08-06 2018-12-05 Takeda Pharmaceutical Company Limited Method for producing dopaminergic neurons
AU2014352773B2 (en) * 2013-11-21 2021-04-29 Memorial Sloan-Kettering Cancer Center Specification of functional cranial placode derivatives from human pluripotent stem cells
US9830679B2 (en) 2014-03-25 2017-11-28 Google Llc Shared virtual reality
AU2016270793B2 (en) 2015-06-01 2022-06-09 Memorial Sloan-Kettering Cancer Center Methods of in vitro differentiation of midbrain dopamine (MDA) neurons

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014532440A (ja) 2011-11-04 2014-12-08 メモリアル スローン−ケタリング キャンサー センター 移植用中脳ドーパミン（ｄａ）ニューロン
WO2015143342A1 (en) 2014-03-21 2015-09-24 Cellular Dynamics International, Inc. Production of midbrain dopaminergic neurons and methods for the use thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NATURE BIOTECHNOLOGY，2009,vol.27,no.3，p.275-280
Nature，2011,vol.480,p.547-551,methods

Also Published As

Publication number Publication date
DK3500664T3 (da) 2021-12-06
AU2021225187A1 (en) 2021-09-30
CA3033205A1 (en) 2018-02-22
JP2022078245A (ja) 2022-05-24
EP4328301A2 (en) 2024-02-28
CN117467608A (zh) 2024-01-30
AU2017313065A1 (en) 2019-02-28
KR20220088800A (ko) 2022-06-28
AU2017313065B2 (en) 2021-06-24
EP4328301A3 (en) 2024-06-19
KR20190039434A (ko) 2019-04-11
EP3500664A1 (en) 2019-06-26
US20180051248A1 (en) 2018-02-22
WO2018035214A8 (en) 2018-05-03
KR102487142B1 (ko) 2023-01-12
EP4001403A1 (en) 2022-05-25
JP7600165B2 (ja) 2024-12-16
JP2019531062A (ja) 2019-10-31
ES2901379T3 (es) 2022-03-22
US10590383B2 (en) 2020-03-17
US20200172862A1 (en) 2020-06-04
EP3500664B1 (en) 2021-09-22
AU2021225187B2 (en) 2024-01-04
CN109844102B (zh) 2023-11-10
WO2018035214A1 (en) 2018-02-22
KR102625865B1 (ko) 2024-01-16
CN109844102A (zh) 2019-06-04

Similar Documents

Publication Publication Date Title
JP7600165B2 (ja) 多能性細胞を分化させるための方法
US10828335B2 (en) Production of midbrain dopaminergic neurons and methods for the use thereof
DK2694644T3 (en) Priming of pluripotent stem cells for neural differentiation
JP6789814B2 (ja) 腺性下垂体又はその前駆組織の製造方法
US20240219375A1 (en) Dopaminergic precursor cells and methods of use
HK40105534A (zh) 多巴胺能前体细胞及使用方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190827

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200424

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210525

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210824

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20211109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220309

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220309

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220317

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220322

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220517

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220606

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220712

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220804

R150 Certificate of patent or registration of utility model

Ref document number: 7120993

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250